Pharmafile Logo
Pharmafocus logo
Advanced Search

Depomed

Showing 8 posts of 8 posts found.

stocks1

Weekly Movers: Valeant, Depomed, Intercept Pharma, Insys Therapeutics and more…

April 18, 2016
Manufacturing and Production, Research and Development, Sales and Marketing Depomed, Intercept Pharma, Relypsa, Share price, Stock Movement, Valeant, stock market

Troubles don’t seem to go away for Canada-based Valeant Pharma (NYSE: VRX) with news of a probable sale doing the …

Feature
money_pills_2

Depomed criticised by investors and urged to explore potential sale

April 11, 2016
Sales and Marketing Depomed, board, horizon, sale, starboard, starboard value

Only a few short months after fighting off a $1 billion bid from Horizon Pharma, investors at Depomed have called …

News

Horizon Pharma receives third rejection from Depomed

August 21, 2015
Sales and Marketing Depomed, Horizon Pharma, pharma mergers and acquisitions

Depomed has announced that its board has unanimously rejected Horizon Pharma’s third proposal to buy the California-based company. Following its …

News
Nucynta (tapentadol)

Takeover hostilities resume between Depomed and Horizon

August 10, 2015
Sales and Marketing Depomed, horizon, hostile bid, nucynta, takeover, tapentadol

The bitter takeover row between Horizon and Depomed has escalated after Depomed dismissed its suitor’s latest advances, and warned it …

News
depomedlogo

Depomed rejects Horizon’s latest takeover bid

July 30, 2015
Sales and Marketing Depomed, horizon, mergers and acquisitions, takeovers

Depomed has rejected Horizon Pharma’s latest bid, stating the proposal is ‘inadequate’ and ’undervalues’ the company. The Irish pharma company …

News
Deopmed logo

Horizon attempts a hostile $3bn Depomed takeover

July 9, 2015
Manufacturing and Production, Research and Development, Sales and Marketing Depomed, M&A, MA, acquisitions, horizon, mergers, takeover

Dublin-based specialty pharmaceutical company Horizon has launched a bid to buy Depomed for $3 billion. Horizon, a biopharma company focussed …

News
srinivas_g

Depomed hires Kyalin chief executive

July 21, 2014
Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Depomed, Srinivas Rao

California-based speciality pharma firm Depomed has appointed Dr Srinivas Rao as its chief medical officer (CMO) and senior VP. Rao …

Appointment

Depomed pulls diabetes drug Glumetza

June 21, 2010
Manufacturing and Production Depomed, Glumetza, manufacturing compliance

Another pharmaceutical manufacturer has been forced to recall products because of contamination caused by a chemical used to treat wooden …

News

Latest content

AbbVie invests €150m in new R&D facility in Germany

May 3, 2024

AstraZeneca shares positive interim results from phase 3 lymphoma trial

May 3, 2024

Merck shares data from phase 3 trial of Keytruda for gastric cancers

May 2, 2024

Verona Pharma to share phase 3 COPD trial data at ATS 2024

May 2, 2024

Beckman Coulter Life Sciences and Watchmaker Genomics enter collaboration

May 1, 2024